Terence Flynn
Stock Analyst at Morgan Stanley
(4.34)
# 381
Out of 5,124 analysts
229
Total ratings
61.54%
Success rate
12.86%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Equal-Weight | $28 → $27 | $25.70 | +5.06% | 21 | Dec 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $190 → $197 | $206.13 | -4.43% | 26 | Dec 12, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $37 | $54.51 | -32.12% | 12 | Dec 12, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $100 → $102 | $109.24 | -6.62% | 20 | Dec 12, 2025 | |
| GPCR Structure Therapeutics | Maintains: Overweight | $120 → $125 | $65.72 | +90.22% | 2 | Dec 12, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $329 → $304 | $324.14 | -6.21% | 11 | Dec 12, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $261 → $269 | $222.55 | +20.87% | 19 | Dec 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $516 → $564 | $467.71 | +20.59% | 3 | Dec 5, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,171 → $1,290 | $1,062.98 | +21.36% | 23 | Nov 24, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $54 → $26 | $9.53 | +172.82% | 4 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $9 | $7.93 | +13.49% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $17.65 | -14.99% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $54 | $40.79 | +32.39% | 13 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $131 | $98.48 | +33.02% | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $512.59 | -15.14% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $18.02 | +22.12% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $23 | $21.51 | +6.93% | 8 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $11.90 | -7.56% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $59.10 | -45.85% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $9.83 | +11.90% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.06 | +288.35% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $181.22 | +140.59% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $387.55 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.23 | - | 1 | Jul 21, 2017 |
Pfizer
Dec 17, 2025
Maintains: Equal-Weight
Price Target: $28 → $27
Current: $25.70
Upside: +5.06%
Johnson & Johnson
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $190 → $197
Current: $206.13
Upside: -4.43%
Bristol-Myers Squibb Company
Dec 12, 2025
Maintains: Underweight
Price Target: $36 → $37
Current: $54.51
Upside: -32.12%
Merck & Co.
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $100 → $102
Current: $109.24
Upside: -6.62%
Structure Therapeutics
Dec 12, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $65.72
Upside: +90.22%
Amgen
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $329 → $304
Current: $324.14
Upside: -6.21%
AbbVie
Dec 12, 2025
Maintains: Overweight
Price Target: $261 → $269
Current: $222.55
Upside: +20.87%
Vertex Pharmaceuticals
Dec 5, 2025
Maintains: Overweight
Price Target: $516 → $564
Current: $467.71
Upside: +20.59%
Eli Lilly and Company
Nov 24, 2025
Maintains: Overweight
Price Target: $1,171 → $1,290
Current: $1,062.98
Upside: +21.36%
Biohaven
Nov 18, 2025
Maintains: Overweight
Price Target: $54 → $26
Current: $9.53
Upside: +172.82%
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $7.93
Upside: +13.49%
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $17.65
Upside: -14.99%
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $40.79
Upside: +32.39%
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $98.48
Upside: +33.02%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $512.59
Upside: -15.14%
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $18.02
Upside: +22.12%
Aug 7, 2025
Maintains: Overweight
Price Target: $22 → $23
Current: $21.51
Upside: +6.93%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $11.90
Upside: -7.56%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $59.10
Upside: -45.85%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $9.83
Upside: +11.90%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.06
Upside: +288.35%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $181.22
Upside: +140.59%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $387.55
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.23
Upside: -